VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 3, 2026
Stock Comparison
AstraZeneca PLC vs NIKE, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisNIKE, Inc.
NKE · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 70 / 100 for NIKE, Inc.).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); NIKE, Inc. has 3 segments (57.8% in Wholesale).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; NIKE, Inc. has 6 across 4.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
NIKE, Inc.
Wholesale
Branded athletic & casual footwear/apparel wholesale distribution
Global
Retailers, distributors, licensees
Brand owner / wholesaler
57.8%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
NIKE, Inc. strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
NIKE, Inc. segments
Full profile >Wholesale
Competitive
Direct to Consumer (DTC)
Competitive
Brand licensing & other
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.